~~<i id='03884B299C'><strike id='03884B299C'><tt id='03884B299C'><pre id='03884B299C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：explore 2025-08-12 08:27:55 - browse：59

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： STAT Virtual Event: Putting AI to the Test

focus

leisure time

knowledge

entertainment

knowledge

focus

AdobeWhenapediatricianputMayaProkupetsonthebirthcontrolpillatage15topreventpregnancy,shedoesn’tremem

WSS

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Biogen nominates mother of director’s child to replace him on board

EpiPen alternative approval delay highlights citizen petition issue

Microbiome research is starting to find links to chronic diseases

Experts study whether long Covid risk adds up with each reinfection

FDA panel to weigh approval of NurOwn, controversial ALS drug

explore

hotspot

focus

Medical leaders decry Supreme Court decision on affirmative action

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Sports medicine is finally prioritizing gender equality

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Tori Bowie and the unacceptable rates of Black maternal death

Senators: Long

As demand for Covid shots wanes, Moderna seeks its next success

A public health expert passes on football's full body collisions for youths

Hollywood unions extend contract negotiations for actors

How AI helped researchers track recovery from depression

leisure time

Senators: Long

Second xenotransplant done with gene

Biotech stock slump in 2023: awaiting the turnaround

It's been 20 years since Dolly the sheep. Where's my clone?

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Senate HELP committee spars over health care workforce policies

knowledge

entertainment

knowledge

focus